Communiqués Inhibikase Therapeutics, Inc.

Actions

IKT

US45719W2052

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 27/06/2024			Varia. 5j.	Varia. 1 janv.
1,37 ^USD	-2,84%		-4,20%	+7,87%

17/06	Inhibikase Therapeutics complète le recrutement de l'étude de phase 2 " 201 " évaluant le risvodétinib dans le traitement de la maladie de Parkinson non traitée. évaluant le risvodétinib dans le traitement de la maladie de Parkinson non traitée	CI
05/06	Inhibikase Therapeutics, Inc. annonce l'élargissement de son portefeuille thérapeutique	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Inhibikase Therapeutics Completes Enrollment of the Phase 2 201 Trial Evaluating Risvodetinib in Untreated Parkinson s disease	18/06	AQ
Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease	17/06	GL
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs	05/06	GL
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million	20/05	GL
Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity	16/05	GL
Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement	15/05	GL
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension	09/05	GL
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs	18/04	GL
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension	03/04	GL
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity	27/03	GL
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders	07/03	GL
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro	28/02	GL
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers	07/02	GL
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers	07/02	AQ
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI	30/01	AQ
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib	29/01	GL
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib	29/01	AQ
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli	16/01	GL
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs	19/12	GL
Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro	04/12	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Inhibikase Therapeutics, Inc.

Actions

IKT

US45719W2052

Communiqués

Filtres